Core Viewpoint - The stock of 加科思-B (01167) has seen a significant increase of over 6%, currently trading at 6.06 HKD with a transaction volume of 14.5881 million HKD, following the announcement of a collaboration with AstraZeneca on its proprietary Pan-KRAS inhibitor JAB-23E73 [1] Group 1: Company Developments - 加科思 announced a collaboration with AstraZeneca regarding its Pan-KRAS inhibitor JAB-23E73 in December last year [1] - The company’s core pipeline product, JAB-23E73, is projected to achieve a peak sales revenue of 1.2 billion RMB in the domestic market, adjusted for risk [1] - In the overseas market, the peak sales revenue for JAB-23E73 is expected to reach 1.9 billion USD, with an unadjusted figure of 7.2 billion USD [1] Group 2: Market Impact - The KRAS G12C inhibitor, 戈来雷塞, is set to be included in the national medical insurance directory starting January 2026, which is anticipated to drive rapid sales growth under the commercialization efforts of 艾力斯 [1]
港股异动 | 加科思-B(01167)午后涨超6% JAB-23E73全球开发进程加速 戈来雷塞有望快速放量